Breakthrough infections due to SARS-CoV-2 Wild type, the Delta variant and the Omicron variant in early fourth wave of epidemics in Myanmar
Main Article Content
Abstract
The “severe acute respiratory syndrome coronavirus type 2” (SARS-CoV-2) is also known as “coronavirus disease 19” (COVID-19). It originated in Wuhan, Hubei province, People’s Republic of China, in December 2019; and, it spread worldwide causing a global pandemic. Genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic namely the original (wild-type), the Alpha variant, the Beta variant, the Delta variant, and the Gamma variant. In third wave, the notorious variant was the Delta variant; it was well-known for quick transmissibility, causing high morbidity and mortality. In late November 2021, the Omicron variant was first detected in South Africa.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Brandal, L. T., MacDonald, E., Veneti, L., Ravlo, T., Lange, H., Naseer, U., Feruglio, S., Bragstad, K., Hungnes, O., Ødeskaug, L. E., Hagen, F., Hanch-Hansen, K. E., Lind, A., Watle, S. V., Taxt, A. M., Johansen, M., Vold, L., Aavitsland, P., Nygård, K., & Madslien, E. H. (2021). Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. In Eurosurveillance (Vol. 26, Issue 50, p. 2101147).
Chau, N. V. V., Ngoc, N. M., Nguyet, L. A., Quang, V. M., Ny, N. T. H., Khoa, D. B., Phong, N. T., Toan, L. M., Hong, N. T. T., Tuyen, N. T. K., Phat, V. V., Nhu, L. N. T., Truc, N. H. T., That, B. T. T., Thao, H. P., Thao, T. N. P., Vuong, V. T., Tam, T. T. T., Tai, N. T., … Tan, L. V. (2021). An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine, 41. https://doi.org/10.1016/j.eclinm.2021.101143
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M. G., Al Romaihi, H. E., … Abu-Raddad, L. J. (2021). Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. The New England Journal of Medicine, 385(24), e83. https://doi.org/10.1056/NEJMoa2114114
Chia, P. Y., Ong, S. W. X., Chiew, C. J., Ang, L. W., Chavatte, J.-M., Mak, T.-M., Cui, L., Kalimuddin, S., Chia, W. N., & Tan, C. W. (2021). Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study. Clinical Microbiology and Infection.
Danza, P., Koo, T. H., Haddix, M., Fisher, R., Traub, E., Yong, K. O., & Balter, S. (2022). SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance—Los Angeles County, California, November 7, 2021–January 8, 2022 (p. 71(5);177-181). https://www.cdc.gov/mmwr/volumes/71/wr/mm7105e1.htm
de Gier, B., Andeweg, S., Backer, J. A., Hahné, S. J., van den Hof, S., de Melker, H. E., & Knol, M. J. (2021). Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B. 1.617. 2), the Netherlands, August to September 2021. Eurosurveillance, 26(44), 2100977.
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., Zervos, M., Rankin, B., Eder, F., Feldman, G., Kennelly, C., Han-Conrad, L., Levin, M., Neuzil, K. M., Corey, L., … Miller, J. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. New England Journal of Medicine, 385(19), 1774–1785. https://doi.org/10.1056/NEJMoa2113017
Eyre, D. W., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K., Walker, A. S., & Peto, T. E. (2021). The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission. Medrxiv.
Hansen, C. H., Schelde, A. B., Moustsen-Helm, I. R., Emborg, H.-D., Krause, T. G., Mølbak, K., Valentiner-Branth, P., & on behalf of the Infectious Disease Preparedness Group at Statens Serum Institut. (2021). Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. MedRxiv, 2021.12.20.21267966. https://doi.org/10.1101/2021.12.20.21267966
Htun, Y. M., Win, T. T., Aung, A., Latt, T. Z., Phyo, Y. N., Tun, T. M., Htun, N. S., Tun, K. M., & Htun, K. A. (2021). Initial presenting symptoms, comorbidities and severity of COVID-19 patients during the second wave of epidemic in Myanmar. Tropical Medicine and Health, 49(1), 62. https://doi.org/10.1186/s41182-021-00353-9
Jin, Y., Hou, C., Li, Y., Zheng, K., & Wang, C. (2022). mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.821538
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2021). Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nature Medicine, 27(12), 2108–2110. https://doi.org/10.1038/s41591-021-01575-4
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., & Tartof, S. Y. (2022). Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. MedRxiv, 2022.01.11.22269045. https://doi.org/10.1101/2022.01.11.22269045
Our World in Data. (2022). Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations?country=OWID_WRL
Public Health Ontario. (2021). COVID-19 Variant of Concern Omicron (B.1.1.529). https://www.publichealthontario.ca/-/media/documents/ncov/voc/2022/01/covid-19-omicron-b11529-risk-assessment-jan-12.pdf?sc_lang=en
Pyar, K. P., Hla, S., Min, A., Wunn, D., Aung, Z. N., Lin, M., Win, T., Aung, L., Kyaw, A., Ya, K., Tun, T., Kyaw, M., Oo, Z., Aung, Z., Lin, T., & Htun, S. (2021). Breakthrough Infection among Fully Vaccinated Physicians Working in COVID-19 Treatment Centers; Prevalence, Presenting Symptoms, Co-Morbidities and Outcome in the Third Wave of Epidemics in Myanmar. Journal of Biomedical Research & Environmental Sciences, 2, 721–730. https://doi.org/10.37871/jbres1303
Shah, A. S., Gribben, C., Bishop, J., Hanlon, P., Caldwell, D., Wood, R., Reid, M., McMenamin, J., Goldberg, D., & Stockton, D. (2021). Effect of vaccination on transmission of SARS-CoV-2. New England Journal of Medicine, 385(18), 1718–1720.
Sheikh, A., Kerr, S., Woolhouse, M., McMenamin, J., & Robertson, C. (2021). Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: National cohort with nested test negative design study in Scotland. University of Edinburgh Research Explorer. https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-
Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet (London, England), 398(10309), 1407–1416. https://doi.org/10.1016/S0140-6736(21)02183-8
Tenforde, M. W., Self, W. H., Adams, K., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … Influenza and Other Viruses in the Acutely Ill (IVY) Network. (2021). Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA, 326(20), 2043–2054. https://doi.org/10.1001/jama.2021.19499
UK Health Security Agency. (2021). SARS-CoV-2 variants of concern and variants under investigation in England. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf
Wang, L., Berger, N. A., Kaelber, D. C., Davis, P. B., Volkow, N. D., & Xu, R. (2022). Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. MedRxiv, 2021.12.30.21268495. https://doi.org/10.1101/2021.12.30.21268495
World Health Organization. (2021). Update on Omicron. https://www.who.int/news/item/28-11-2021-update-on-omicron
World Health Organization. (2022). COVID-19 vaccines. https://app.powerbi.com/view?r=eyJrIjoiMWNjNzZkNjctZTNiNy00YmMzLTkxZjQtNmJiZDM2MTYxNzEwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9
Yi, S., Kim, J. M., Choe, Y. J., Hong, S., Choi, S., Ahn, S. B., Kim, M., & Park, Y.-J. (2022). SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household. Journal of Korean Medical Science, 37(1), e12. https://doi.org/10.3346/jkms.2022.37.e12
Zoe Covid Study Group. (2022, January 18). What are the symptoms of Omicron? https://joinzoe.com/learn/omicron-symptoms